Comparative Pharmacology
Head-to-head clinical analysis: NEOSAR versus THIOTEPA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOSAR versus THIOTEPA.
NEOSAR vs THIOTEPA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent that inhibits DNA replication and transcription by cross-linking DNA strands, leading to cell cycle arrest and apoptosis.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription.
Cyclophosphamide 500-1500 mg/m² IV every 2-4 weeks; oral 50-200 mg daily.
0.3-0.4 mg/kg intravenously every 1-4 weeks; or 0.5-1 mg/kg intravenously every 2-4 weeks (commonly 60 mg/m² IV every 1-4 weeks).
None Documented
None Documented
Terminal elimination half-life: 3-5 hours; prolonged in hepatic impairment (up to 12 hours).
Clinical Note
moderateThiotepa + Digoxin
"Thiotepa may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateThiotepa + Digitoxin
"Thiotepa may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateThiotepa + Deslanoside
"Thiotepa may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateThiotepa + Acetyldigitoxin
"Thiotepa may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 1.5-4.5 hours. Clinically, due to rapid clearance, dosing intervals are typically every 1-4 weeks.
Renal: 30-60% unchanged; biliary/fecal: 10-20% as metabolites.
Primarily renal; 60-70% excreted unchanged in urine within 24-72 hours. Minor biliary/fecal elimination accounts for <10%.
Category C
Category D/X
Alkylating Agent
Alkylating Agent